For Healthcare Professionals

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)


About the study

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Age greater than or equal to 18 at the time of enrollment
  2. Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
  3. Eastern Cooperative Oncology Group performance status 0 or 1
  4. Adequate hematologic, renal, liver, cardiac and pulmonary organ function


Exclusion Criteria:

  1. Prior therapy with an anti-CD19 targeting agent
  2. Active or chronic graft versus host disease requiring therapy
  3. Prior allogeneic stem cell transplantation
  4. Central nervous system (CNS) lymphoma, prior CNS malignancy
  5. Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
  6. Primary immunodeficiency
  7. Current or expected need for systemic corticosteroid therapy
  8. Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
  9. Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
  10. Unwillingness to follow extended safety monitoring
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Lymphoma, Non-Hodgkin,Relapsed Non Hodgkin Lymphoma,Refractory B-Cell Non-Hodgkin Lymphoma,Non Hodgkin Lymphoma,Lymphoma,B Cell Lymphoma,B Cell Non-Hodgkin's Lymphoma

Age (in years)



Phase 1

Participants needed


Est. Completion Date

Sep 30, 2025

Treatment type



Caribou Biosciences, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.